Johnson & Johnson (NYSE:JNJ) Shares Sold by Morgan Dempsey Capital Management LLC

Morgan Dempsey Capital Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 16.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,624 shares of the company’s stock after selling 6,635 shares during the quarter. Johnson & Johnson comprises 2.0% of Morgan Dempsey Capital Management LLC’s investment portfolio, making the stock its 28th biggest position. Morgan Dempsey Capital Management LLC’s holdings in Johnson & Johnson were worth $5,007,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the period. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $35,000. Activest Wealth Management purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $40,000. Finally, Fiduciary Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $43,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on JNJ. Bank of America reduced their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley cut their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Up 1.2 %

NYSE JNJ opened at $167.08 on Tuesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a market capitalization of $402.26 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The firm has a 50 day moving average of $151.33 and a two-hundred day moving average of $156.08.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.